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The pharmacological activity of different nuclear
receptor ligands is reflected by their impact on
receptor structure.Thus,weaskedwhetherdifferential
presentation of protein-protein interaction surfaces on
the androgen receptor (AR), a surrogate assay of
receptor conformation, could be used in a prospective
manner to define the pharmacological activity of
bound ligands. To this end, we identified over 150
proteins/polypeptides whose ability to interact with
AR is influenced in a differential manner by ligand
binding. The most discriminatory of these protein-AR
interactions were used to develop a robust com-
pound-profiling tool that enabled the separation of
ligands into functionally distinguishable classes.
Importantly, the ligands within each class exhibited
similar pharmacological activities, a result that high-
lights the relationship between receptor structure
and activity and provides direction for the discovery
of novel AR modulators.
INTRODUCTION
The steroid receptor subfamily of ligand-regulated transcription
factors comprises well-validated drug targets, modulators of
which are used extensively in the clinic to manipulate normal
endocrine signaling or to block inappropriate cellular responses
to specific hormones. Until recently, the most pharmaceutically
important modulators of these receptors were agonists that
mimicked the actions of physiological hormones or antagonists
that opposed the actions of endogenous activating ligands.
However, there has been a significant paradigm shift in this
area of drug discovery fuelled by the observation that the
complex signaling pathways regulated by steroid hormones
can be exploited to yield compounds that manifest cell and/or452 Chemistry & Biology 16, 452–460, April 24, 2009 ª2009 Elsevieprocess selectivity. The practical impact of this observation
was highlighted by a seminal study demonstrating that tamox-
ifen, an antiestrogen in breast, actually functioned as an
estrogen in the skeletal system (Love et al., 1992). Thus, it ap-
peared that tamoxifen, rather than functioning as an antagonist
in all tissues, is actually a selective estrogen receptor modulator
(SERM), a compound whose relative agonist/antagonist activi-
ties are manifest in a cell-selective manner (Sato et al., 1996).
Subsequently, other SERMs, like raloxifene, have been devel-
oped for the treatment and prevention of postmenopausal oste-
oporosis (Cole et al., 1998). However, the observation that
tamoxifen, and now raloxifene, also significantly reduce the inci-
dence of breast cancer in patients at elevated risk for the disease
has clearly demonstrated the benefit of developing compounds
with dual agonist/antagonist activities (Vogel et al., 2006). The
clinically favorable profile of this new class of drug has reinvigo-
rated the field with the anticipation that, by understanding their
mechanism of action, it will be possible to develop SERMs
with more useful therapeutic activities. In addition, the clinical
success of SERMs has resulted in a heightened level of interest
in developing selective modulators of the progesterone, mineral-
ocorticoid, glucocorticoid, and androgen receptors for the treat-
ment of a variety of different endocrinopathies.
Our interests have focused recently on the development and
application of mechanism-based approaches to discover new
classes of androgen receptor (AR) modulators. Androgens are
key regulators of processes involved in the development and
maintenance of normal reproductive function in males and also
exert significant anabolic actions in both bone and skeletal
muscle. Not surprisingly, therefore, in addition to the treatment
of hypogonadism, there is a high level of interest in using andro-
gens for the treatment of sarcopenia, osteoporosis, and muscle
wasting associated with certain diseases (including cancer and
AIDS) (Cadilla and Turnbull, 2006; Negro-Vilar, 1999). However,
androgens and aberrant AR signaling have also been implicated
in the pathology of benign prostatic hypertrophy and prostate
cancer, raising the concern that chronic administration of AR
agonists might have a negative effect on prostate health. Thus,r Ltd All rights reserved
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ment (and possible prevention) of prostate cancer, there is an
unmet medical need for AR ligands that exhibit anabolic activity
in muscle and bone but have reduced activity in the prostate.
Several drugs with these general characteristics, comprising a
subclass of AR ligands called selective androgen receptor
modulators (SARMs), have been identified and are currently
being evaluated in the clinic for a variety of conditions (Gao
and Dalton, 2007). However, the molecular basis for the selec-
tivity of this class of drugs has not been established, and it is
not clear if they represent the optimal modulators of AR signaling
for clinical use. For this reason, there is a need to understand the
molecular mechanisms that determine the pharmacological
activity of AR ligands to direct the discovery of the next genera-
tion of process-specific modulators.
Much of what is known about the molecular determinants of
nuclear receptor (NR) pharmacology has come from the study
of the SERMs tamoxifen and raloxifene. Using differential sensi-
tivity to proteases, it was shown that these SERMs induced
a conformational change in estrogen receptor alpha (ERa) that
was distinct from that observedwhen the receptor was occupied
by either agonists or pure antagonists (McDonnell et al., 1995).
Subsequent crystallographic analysis of the isolated hormone
binding domain of ERa occupied with 17b-estradiol, or with
different SERMs, confirmed these alterations in receptor struc-
ture andmapped amajor conformational change to the AF-2 co-
activator interaction domain locatedwithin the carboxyl terminus
of the receptor (Brzozowski et al., 1997; Shiau et al., 1998; Wu
et al., 2005). Studies using combinatorial peptide phage display
highlighted the dynamic, flexible nature of the AF-2 pocket and
how this was influenced by different SERMs (Connor et al.,
2001; Norris et al., 1999). However, although these studies of
ER structure and AF-2 architecture revealed how SERMs func-
tioned as antagonists in some contexts, they did not explain
the dramatic functional differences exhibited by tamoxifen and
raloxifene in the reproductive system. This raised the possibility
that protein-protein interaction surfaces, in addition to AF-2, are
presented on the surface of SERM-activated ER, allowing it to
engage cofactors that promote agonist activity in some tissues.
Indeed, this idea is supported by mutagenesis studies showing
that domains other than AF-2 are required for SERM agonist
activity (Tzukerman et al., 1994).
Although crystallography and combinatorial peptide phage
display have been useful in understanding the role of agonists
and antagonists in the presentation of the AF-2 cofactor-binding
pocket within AR (Chang and McDonnell, 2005; Matias et al.,
2000;Ostrowski et al., 2007;Wang et al., 2006), neither approach
has been informative with respect to the impact of ligands on the
presentation of surfaces, other than AF-2, that are likely to be
involved in cofactor binding. This is somewhat surprising
because there is a significant amount of biochemical data to
suggest that AR function is influenced by ligand-regulated intra-
domain interactions (He et al., 2000; He and Wilson, 2002).
Thus, it is likely that structurally complex, protein-protein interac-
tion surfaces are lost in studies of isolated domains. This problem
might also apply to the use of short peptide probes to study AR
structure, because theymight be unable to interact with complex
binding surfaces that require intradomain interactions. To over-
come these limitations,we have usedT7phagedisplay to identifyChemistry & Biology 16proteins/peptides whose interaction with full-length AR is influ-
enced by the nature of the bound ligand. Although it is unlikely
that all of the proteins/polypeptides identified are derived from
physiologically relevant AR cofactors, we have shown that they
provide sufficient structural complexity to enable an evaluation
of the role of ligands in regulating the presentation of different
protein-protein interaction surfaces on AR. Furthermore, we
have demonstrated that the differential presentation of protein-
protein interaction surfaces by AR ligands can be used in a
prospective manner to predict their inherent pharmacological
activities.
RESULTS
Identification of AR-Interacting Proteins
AR is a large, multidomain transcription factor whose functional
activity requires both intramolecular interactions between
receptor domains and intermolecular interactions with cofactors
and DNA (Chang and McDonnell, 2005; He and Wilson, 2002).
Given the difficulty of defining multiple protein-protein interac-
tion surfaces on the receptor using combinatorial peptide phage
display (Norris et al., 1999), we reasoned that many of the
surfaces on AR that are required for activity are diffuse and
complex. Thus, the interaction domain(s) of some associated
proteins are likely to be relatively large and would not be ex-
pected to be identifiable using small peptides. Consequently,
we initiated a project directed toward the identification of intact
proteins (or protein fragments) that could be used to survey the
protein-protein interaction surfaces presented on ligand-acti-
vated AR. To this end, high-throughput T7 phage display tech-
nology was used to screen cDNA expression libraries derived
from androgen responsive tissues and cell lines (human liver,
human kidney, human muscle, human prostate, LNCaP, and
rat levator ani) for proteins that interact in a specific manner
with ligand-bound AR (Figure 1A). Although the identification of
protein probes of AR structure was the primary goal of this
project, we reasoned that by using phage libraries derived
from AR-expressing cells we could also identify functionally rele-
vant cofactors.
For these screens, recombinant biotinylatedAR (full-lengthAR,
amino acids [aa] 1–919; AR-LBD, aa 507–919; and ARN-term, aa
1–660) (Figure 1A) was purified from Spodoptera frugiperda cells
in the presence of either agonists (R1881, dihydrotestosterone
[DHT]) or SARMs (LG2226, S4, GW579, GW980) (Juzumiene
et al., 2005) and immobilized to 96 well plates using the C3
androgen response element (ARE) (Kallio et al., 1994). The immo-
bilized AR was used as bait in screens for T7 phage expressing
AR-interacting proteins. Prior to screening, we confirmed that
biotinylation of AR did not have a negative impact on its function
by demonstrating that this modified form of the receptor was
transcriptionally active inmammalian cells (not shown). Following
sequence analysis and in silico characterization of the cDNA
inserts from more than 4900 purified phage, we identified 309
nonredundant clones whose expressed products interacted
with AR (Figure 1A). The identity of the proteins corresponding
to each clone and additional details of the screen are presented
in Table S1 (available online). Several previously identified
AR- and NR-interacting proteins were identified in this screen
including ARA24, gelsolin, PTEN, TFIIF, supervillin, HOXB13,, 452–460, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 453
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Display
(A) Scheme used for affinity selection of AR-interacting proteins. Tissue
specific T7 phage display libraries (human prostate, human muscle, human
kidney, human liver, LNCaP, and rat levator ani) were incubated with AR target
protein (AR-FL, aa 1–919; AR-LBD, aa 507–919; and AR N-term, aa 1–660)
bound by ligand (R1881, DHT, SARM). Unbound phage were removed by
washing and bound phage were eluted and amplified. The process was
repeated for a total of five rounds of panning. Individual phage were plaque
purified and identity of AR-interacting protein was deduced by DNA
sequencing. A summary of the screening results is shown in the table (inset).
In total, 4922 individual phage were sequenced, resulting in 309 nonredundant
clones (Table S1).
(B) A mammalian two-hybrid assay was used to evaluate ligand-dependent
recruitment of selected T7 clones with AR in cells. HepG2 cells were trans-
fected with AR-VP16 and indicated T7 clone (expressed as a fusion with the
Gal4 DNA binding domain) along with the Gal4- responsive reporter gene
(5xGalLuc3) and pCMV-bGal. Cellswere induced for 48 hrwith indicated ligand
(100 nM for all ligands except bicalutamide [bic], whichwas used at 1 uM). Data
are presented as normalized response, which was obtained by normalizing
luciferase activity to b-galactosidase activity. ARA54, positive control;
zsGreen, negative control; VP16, empty VP16 vector in place of AR-VP16.
The data are representative of three separate experiments. The error bars
represent the standard deviation of a single experiment performed in triplicate.TRIP12, and PPARBP (Hsiao et al., 1999; Jung et al., 2004; Lee
et al., 1995; Lin et al., 2004; McEwan and Gustafsson, 1997;
Ting et al., 2002; Wang et al., 2002). The identification of multiple
alleles of known AR- and NR-interacting proteins served as an
initial validation of the approach we used to identify protein
domains that were capable of highlighting functionally important
protein-protein interactions surfaces on the receptor. Impor-454 Chemistry & Biology 16, 452–460, April 24, 2009 ª2009 Elseviertantly, several proteins were identified that interact with the
N terminus of AR and are thus independent of AF-2 (Table S1).
A gene ontology analysis of the primary AR interactors indi-
cated that several protein classes were overrepresented in this
collection compared with a reference protein module using
ONTO-tools (Khatri et al., 2004). As expected, proteins involved
in gene expression and nucleotide binding were the most over-
represented, followed by proteins involved in metal ion binding
and cytoskeletal interactions (see Figure S1). Interestingly, the
previously defined cofactors that contain the NR- interaction
motifs LXXLL (Chang et al., 1999; Heery et al., 1997) and FXXLF
(AR-cofactors) (He et al., 2000, 2002) were underrepresented in
the proteins identified in our screens. The specific motifs that
enable the interaction of the proteins identified with AR remain
to be defined.
The ability of each clone, identified in the primary screen, to
interact with AR in cells was examined using a mammalian
two-hybrid assay. Specifically, each clone, expressed as a fusion
protein with the Gal4 DNA binding domain (DBD), was tested for
its ability to interact with full-length AR-VP16 in the presence of
either R1881 or a SARM. Of the 302 clones tested in this manner,
162 were found to interact with AR and were brought forward for
further analysis (Table S1).
Classification of AR-Interacting Proteins Based
on Their Ability to Associate with Different
Receptor-Ligand Complexes
One of the assumptions underlying AR pharmacology is that
ligands regulate the presentation of different protein-protein
interaction surfaces on AR. Thus, we assessed the ability of
each of the 162 proteins identified to interact with AR in the pres-
ence of pharmacologically distinct ligands using a mammalian
two-hybrid assay with a view to separating these proteins into
functionally distinct groups. Representative data highlighting
the impact of ligands on the interaction of AR with selected
proteins are presented in Figure 1B. Interestingly, the previously
identified AR coactivator, ARA54 (Kang et al., 1999), interacts
with AR when bound by all of the ligands tested. However, the
interaction is significantly enhanced in the presence of the
SARM S4 (Yin et al., 2003). SCYL1 exhibits similar preferences
as ARA54, although in this case R1881-activated AR yields the
most robust response. Both DDX3X (a DEAD box RNA helicase)
and DDELF1 (development and differentiation enhancing factor-
like 1) interact with RTI001-activated AR, with DDELF1 also
demonstrating a preference for R1881-bound receptor. Gelsolin,
a previously identified AR coregulatory protein (Nishimura et al.,
2003), interacts with AR in the presence of all ligands tested
including the antagonist bicalutamide. We also identified several
proteins, like MLF2, that interact with apo-AR but whose interac-
tion is significantly diminished in the presence of agonists and
enhanced by bicalutamide. A similar analysis was performed
with each of the 162 confirmed AR interactors. At the conclusion
of these experiments, we were able to define eight distinct
classes of ligand-modulated interaction profiles that best
described the receptor binding characteristics of the 162 inter-
actors. For example, the interaction profiles of proteins in the
same class as ARA54, as described in Figure 1B, were modu-
lated similarly by ligands (S4 > R1881z LG2226 > RTI-001 > bi-
calutamide). These groups were based solely on the interactionLtd All rights reserved
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Defines Distinct Classes of AR Ligands
Mammalian two-hybrid assay was performed as in
Figure 1B except that Renilla-luciferase was used
to normalize for transfection efficiency. Interaction
profiles of 95 androgen receptor ligands and
vehicle controls were generated using eight cofac-
tors. The profiles were analyzed with the Ward
hierarchical cluster algorithm using standardized
data. The resulting dendrogram and structural
activity heatmap demonstrates the relationships
between the ten structure-based clusters. The 25
labeled compounds are AR ligandswith previously
characterized biological activities. Controls are
indicated as DMSO and NH, reflecting the vehicle
alone or no vehicle addition.profile and were derived without regard to the strength of inter-
action. Subsequently, we selected a single, representative pro-
tein/peptide probe from each class, for inclusion in the profiling
tool described below. It is important to note that although we
identified potentially interesting AR-interacting proteins in this
screen, it is their ability to survey the presentation of different
protein-protein interaction surfaces on AR following activation
by different ligands that is the focus of the current study. Thus,
the next step was to determine the extent to which protein-
protein interaction profiles could be used to predict the pharma-
cological activity of AR ligands.
AR Ligands Can Be Distinguished Based on Their Ability
to Present Different Protein-Protein Interaction
Surfaces on the Receptor
Thediverse set ofAR interactingproteinswe identifiedaffordedus
the opportunity to apply a chemical-biological approach to
address the relationship between the presentation of different
protein-protein interaction surfaces and the pharmacological
activityof ligands.Specifically,wescreeneda libraryofstructurally
diverse AR ligands and assessed their ability to differentially regu-
late the interaction of AR with a representative protein probe from
each of the eight groups highlighted by the preliminary studies
described above. The set of compounds chosen for this analysis
includes a number of well-characterized AR ligands; (a) antago-
nists (bicalutamide, hydroxyflutamide [OHF], and LG120907;
Hamann et al., 1998), (b) full agonists (R1881 and DHT), and (c)
SARMs (S4, LG2226, and BMS564929) (Gao and Dalton, 2007;
Miner et al., 2007; Ostrowski et al., 2007; Yin et al., 2003). We
also included a large number of novel ligands that we identified
for which no biology is known but had a Ki of less than 1.0 mM in
AR binding assays (Table S2). The results of this screen are pre-
sented in Figure 2.
To avoid signal strength bias, the interaction data for each indi-
vidual protein was standardized. The individual interaction
profiles were then clustered by hierarchical analysis using the
Ward hierarchical cluster algorithm (Ward, 1963). Ligand cluster
1 contains OHF and bicalutamide and thus represents the inter-
action profile of an antagonist. Cluster 2 contains another group
of antagonists (or very weak agonists), LG120907 and R2 (Dalton
et al., 1998). Cluster 3 represents the protein binding profile of
the receptor in the presence of dimethyl sulfoxide (DMSO) or in
the absence of any compound (apo-receptor). Interestingly, we
identified compounds in this cluster that interact with AR, butChemistry & Biology 16whose protein binding profiles are indistinguishable from the un-
liganded receptor. We predict that compounds in this cluster
could represent pure competitive antagonists that bind and
freeze the receptor into an ‘‘apo’’ conformation. Indeed, cluster
3 ligands were found to inhibit R881-mediated AR transcriptional
activity (Figure S2). Clusters 4 and 5 represent compounds that
display varying degrees of partial agonist properties. Cluster 6
contains most of the RTI series of RU486-derived AR ligands
(Sathya et al., 2003). Both RTI001 and RTI018 are found in this
cluster, although they reside in different nodes, a reflection,
possibly, of the subtle differences in the pharmacological activ-
ities of these ligands that we have observed previously (Kazmin
et al., 2006; Sathya et al., 2003). This cluster also contains unre-
lated nonsteroidal compounds, demonstrating that the peptide
interaction profile likely reflects structural changes in AR, rather
than being related to a particular chemotype. Cluster 7 contains
S4, a compound that has previously been shown to have SARM
activity (Yin et al., 2003). Among the compounds in cluster 8 are
additional SARMs LG2226 and BMS564909, both of which
exhibit prostate sparing properties (Gao and Dalton, 2007; Miner
et al., 2007; Ostrowski et al., 2007; Yin et al., 2003). Cluster 9
contains DHT and testosterone (T) and is populated by most of
the well-studied AR agonists and anabolic steroids. Finally,
cluster 10 contains a single compound with superagonist prop-
erties. Note that the clusters represent distinct protein/peptide
interaction profiles and are not a continuum that represents
a global increase or decrease in the interaction with the selected
probes.
Defining the Relationship between Differential
Presentation of Protein-Protein Interaction
Surfaces and Biological Response
To probe the relationship between the presentation of different
protein-protein interactions surfaces and the pharmacological
activity of bound ligands, we first tested the activity of all 95
compounds in a transient transfectionassayusinganAR-respon-
sive mouse mammary tumor virus (MMTV)-luciferase reporter.
The data from this analysis, presented in Figure 3A, have been
ordered and colored to distinguish the various clusters generated
by the protein interaction studies. Although not absolute, it is
apparent that the relative transcriptional activity of the individual
ligands increases from inactive to active as the cluster numbers
increase. A principal component (PC) analysis was performed
on the dataset presented in Figure 2, and the first three principal, 452–460, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 455
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Induced Conformation and AR Transcrip-
tional Activity
(A) Transcriptional activity of all 95 compounds
from Figure 2 was determined in HepG2 cells
using a MMTV-luciferase reporter assay. Com-
pounds are presented in the same order and
colored by conformation-based clustering as in
Figure 2.
(B) Correlation between AR MMTV-luciferase
activity and conformation. Principle component
analysis was performed using the conformational
data presented in Figure 2. Principle component
1 was plotted versus MMTV-luciferase activity.
Data are plotted as 75% density ellipses in the
color corresponding to the clusters. The dotted line represents the 95% confidence interval, whereas the dashed line represents the 95% prediction interval.
(C) The ability of all 95 compounds from Figure 2 to facilitate the AR N/C-terminal interaction was determined in HepG2 cells. Data are presented as described for
MMTV-luciferase activity in (A).
(D) The correlation between AR N/C-terminal interaction and MMTV-luciferase activity. Compounds are colored according to their conformation cluster.
Data presented in (A) and (C) are representative of two independent experiments. The error bars represent the standard deviation of a single experiment performed
in triplicate.components were plotted against the relative transcriptional
activity of every compound to determine the extent to which the
protein interaction profile correlates with transcriptional activity.
Presented in Figure 3B is the MMTV-luciferase transcriptional
activity plotted against the conformational PC1. As can be
seen, there is a clear correlation between PC1 and relative
MMTV transcriptional activity (R2 = 0.77). These data suggest
that the protein interaction profiles identified are predictive of
the relative agonist, partial agonist, and antagonist activity of
compounds, as assessed using a simple transcriptional assay.
Previously, it has been reported that the ability of compounds
to facilitate an interaction between the amino and carboxyl
termini of AR is a good predictor of agonist efficacy (Kemppainen
et al., 1999).However,wewereunable to establishastrongcorre-
lationbetweenagonist activity andN/C-terminal interaction inour
studies. Cluster 8, for instance, is populated with agonists,
whereas only a subset of these compounds is capable of
promoting N/C-terminal interactions (Figure 3C). Similar results
can be seen with compounds from clusters 5 and 6. When all
compounds are considered, we find only a weak correlation
between activity in the N/C-terminal interaction assay and
MMTV transcription (R2 = 0.38) (Figure 3D).
The next step was to determine whether the correlation
between the protein-protein interaction profiles and the tran-
scriptional activity observed in the transient transfection assays
persisted when an analogous study was performed using
endogenous genes in LaPC4 prostate cancer cells (Klein et al.,
1997). LaPC4 cells were chosen because they contain wild-
type AR and, unlike LNCaP cells that contain a mutated receptor
(T877A), do not exhibit altered ligand specificity. From amicroar-
ray analysis performed in these cells, we chose 24 androgen-
regulated genes (5 androgen-repressed and 19 androgen-acti-
vated genes) to generate an AR gene signature. For this study,
we selected 25 ligands, several from each cluster, and analyzed
their activity on the expression of the selected AR target genes in
LaPC4 cells (Figure 4A). The cluster of origin of each compound
is designated by color as detailed above and in the legend.
Although not identical, the gene expression profile induced by
each of the compounds is highly reflective of the results
observed in the protein interaction assay. This is best exempli-456 Chemistry & Biology 16, 452–460, April 24, 2009 ª2009 Elsevierfied in Figure 4B where the first principal component for each
individual ligand derived from the protein interaction profile is
plotted against the first principal component of the transcrip-
tional dataset. The first principal components from both datasets
are highly correlative (R2 = 0.80), suggesting that the specific
impact of ligands on the presentation of different protein-protein
interaction surfaces is predictive of AR transcriptional activity on
endogenous target genes. Of note was the observation that, in
LaPC4 cells, the clustering of compounds was equally predictive
of target gene repression as it was for target gene activation.
These important results suggest that the surfaces on AR involved
in transcriptional activation might also be involved in transcrip-
tional repression.
We next tested whether the linear correlation between the
protein-protein interaction profiles and transcriptional activity
was also reflected in complex androgen actions (e.g., cell prolif-
eration). Thus, the ability of selected reference AR ligands (20
ligands total with representatives from each cluster) to stimulate
LaPC4 cell proliferation was assessed (Figure 5). As can be seen,
ligands in clusters 1 to 6 stimulate little to no LaPC4 proliferation.
However, with the exception of GW980 in cluster 8, all com-
pounds in cluster 7 and higher stimulate LaPC4 proliferation
with approximately the same efficacy. Interestingly, unlike tran-
scriptional activity, proliferation does not appear to be a graded
response. Instead, the proliferative capacity of the compounds
exhibits a threshold effect with the transition point lying between
clusters 6 and 7. The significance of this finding is currently being
evaluated.
DISCUSSION
It is now generally accepted that the overall conformation of
many NRs is determined by the nature of the bound ligand and
that it is the ability of the cells to distinguish between differently
conformed receptors that dictates pharmacological response.
Central to this hypothesis is the idea that changes in conforma-
tion result in the presentation of different protein-protein interac-
tion surfaces on the receptor and the subsequent recruitment of
functionally distinct cofactors. Indeed, it has been shown that the
relative agonist/antagonist activity of SERMs like tamoxifen andLtd All rights reserved
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scriptional Activity
(A) Dendogram showing relationship of SARMs based on transcriptional
activity of AR gene signature in LaPC4 cells. Gene expression profiles of 19
genes induced and 5 genes repressed by R1881 treatment were generated
using 25 AR ligands and vehicle (DMSO). The profiles were analyzed with
the Ward hierarchical cluster algorithm using standardized data. The confor-
mation-based cluster of each SARM is represented by color as depicted in
Figure 2.
(B) Correlation between endogenous gene transcriptional activity and ligand-
induced AR conformation. Principle component analysis was performed on
the transcriptional data presented in (A) and principle component 1 was
plotted versus the first principle component derived from the conformational
profile (Figure 2).raloxifene can be regulated by manipulating the expression of
selected coactivators and corepressors in cells (Keeton and
Brown, 2005; Shang and Brown, 2002). However, the extent to
which differential protein-protein interactions can be used in
a prospective manner to predict the pharmacological actions
of NR ligands has not been evaluated. In this study, using AR
as a model, we have shown that the presentation of protein-
protein interaction surfaces on this receptor can be regulated
by different ligands and that the resultant profiles are highly
predictive of the biological activity of the receptor. Interestingly,
we did not find any proteins that interact exclusively with one
particular AR-ligand complex. Instead, our studies suggest thatChemistry & Biology 16Figure 5. Ligand-Induced AR Conformation Is Predictive of Prostate
Cancer Cell Proliferation
LaPC4 cells were seeded for 3 days in medium containing charcoal stripped
serum. On days 3, 6, and 9 the cells were treated with the indicated concen-
trations of AR ligand. Each panel represents compound(s) from the conforma-
tional-based compound clusters (1, OHF; 2, - – LG 120907, : – R2; 3,
GW518; 4, A – LG9, - – R16; 5 : – R3, d – LG121071; 6, A – RU486,
- – RTI018; 7, : – S4, d – R9; 8 A – GW980, - – LG2226, : –
BMS564929, d – stanozolol; 9A – GW579,- - testosterone, : – DHT, d –
R1881). Proliferation was determined by measuring total cellular DNA content
on day 10. The data presented are representative of three independent exper-
iments. The error bars represent the standard deviation of a single experiment
performed in triplicate.it is the relative, rather than absolute, binding of interacting
proteins to AR that determines the pharmacological response
of different AR modulators.
One of the interesting observations gleaned from the studies
presented here is that the protein-protein interaction surfaces
on AR presented upon binding the nonsteroidal SARMs, S4
(cluster 7), BMS564929 (cluster 8), and LG2226 (cluster 8), are
similar to those defined by the canonical agonists, DHT and T
(cluster 9). These findings, using full-length AR, are consistent
with recent crystallographic studies that showed that the struc-
ture of the AR-LBD in the presence of either a SARM or a full
agonist were nearly identical (Ostrowski et al., 2007; Wang
et al., 2006). These results are in stark contrast to what has
been observed with ER, where SERMs have been shown to
induce a conformation in ER that is quite distinct from classical
agonists (Brzozowski et al., 1997; Shiau et al., 1998; Wu et al.,
2005). This suggests that although SARMs and SERMs are
similar in that they are both capable of mediating the tissue-
specific agonist activities of their respective receptors, they
differ in the way they achieve this response. SERMs can best
be described as ER antagonists that display partial agonist activ-
ities in some ER-responsive tissues like the uterus and bone, 452–460, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 457
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as strong AR partial agonists whose level of activity is not suffi-
cient to evoke a proliferative response in the prostate. Future
studies will be aimed at examining compounds in clusters with
more antagonist biocharacter (clusters 4–6) in vivo to determine
the extent to which we can ‘‘dial down’’ the protein-protein inter-
action profiles associated with agonists and still retain the
desired anabolic activity without prostate stimulation. Com-
pounds from these clusters might possess more favorable
SARM pharmacological profiles.
Many of the ligands used in the compound-profiling tool are
derived from a similar chemical scaffold(s). Interestingly, subtle
chemical changes in a single scaffold can lead to a diverse set
of molecules, each with a different biocharacter. For example,
many of the sentinel compounds utilized in the profiling tool
were based on the hydroxyflutamide chemical scaffold (Table
S2). These compounds range from full antagonists to partial
agonists with SARM-like properties and can be found populating
conformational clusters 1 through 9. Thus, from a single chemi-
cal scaffold, we can identify and discriminate compounds that
demonstrate considerable diversity with respect to their impact
on the presentation of protein-protein interactions surfaces, an
activity translated into different pharmacological activities.
Importantly, we did not detect a strong correlation between
the activity of compounds in our profiling assay and their chem-
ical structures. One notable exception is the RU486-derived
compounds found primarily populating conformational cluster 6.
Whereas it has been possible to retrospectively define confor-
mational changes in receptor structure that track with specific
pharmacological attributes of NR ligands, it has been difficult
to use conformation alone as a predictive surrogate for the bio-
logical activity of new chemical entities. To circumvent the limi-
tations of both the crystallographic and peptide profiling
approaches, we undertook to develop and validate an assay
that reported on the differential presentation of multiple pro-
tein-protein interaction surfaces on AR upon binding different
ligands. Thus, absent information on the physiological relevance
of the interacting proteins identified, we feel that the approach
taken here and validated in the context of the androgen-signaling
pathway, indicates that the impact of ligands on the presentation
of different protein-protein interaction surfaces is the primary,
predictable determinant of the pharmacological actions of AR
ligands.
SIGNIFICANCE
It is nowwell established that the impact of a given ligand on
NRstructure and theeffect that this hason the recruitment of
functionally distinct cofactors are key determinants of NR
pharmacology. Given this insight, it was hypothesized that
it might be possible to prospectively define the pharmaco-
logical activity of a ligandbyassessing its impact on receptor
structure. Someprogress in this regard hasbeenmadeusing
crystallography to look specifically at the impact of different
ligands on the conformation of the isolated ligand-binding
domain of several receptors (Brzozowski et al., 1997; Matias
et al., 2000; Shiau et al., 1998; Wu et al., 2005). In addition, we
and others have used combinatorial peptide phage displayto survey the presentation of protein-protein interaction
458 Chemistry & Biology 16, 452–460, April 24, 2009 ª2009 Elseviersurfaces, a surrogate for conformation, on ligand-activated
NRs (Connor et al., 2001; Norris et al., 1999; Pearce et al.,
2004). However, although somewhat successful, these
approaches have only been informative with respect to the
impact of ligands on the architecture of a single cofactor-
binding domain on the receptor, the AF-2 coactivator
binding pocket. We report, in this study, on the development
and validation of an approach that circumvents the limita-
tions of previous efforts to link ligand induced changes in
receptor structure to specific pharmacological responses.
Specifically, we selected AR as a model receptor and used
T7 phage display to identify over 150 proteins/polypeptides
whose ability to interact with full-length receptor was influ-
enced by the nature of the bound ligand. A subset of
the proteins identified was subsequently used to develop
a ‘‘profiling’’ tool that allowed us to classify ligands accord-
ing to their ability to engender different AR-protein interac-
tions. Of specific importance was the finding that the phar-
macological activity of previously uncharacterized AR
ligands could be predicted in a prospective manner based
on the protein-protein interactions that they engender. It is
anticipated that in a similar manner it will be possible to
develop compound-profiling tools for other NRs.
EXPERIMENTAL PROCEDURES
Chemicals and Plasmids
5a-Dihydrotestosterone, boldenone, stanozolol, nandrolone, testosterone,
and oxandrolone were purchased from Steraloids (Newport, RI). R1881 was
purchased fromPerkinElmer (Waltham,MA).Hydroxyflutamidewaspurchased
fromTorontoResearchChemicals (Toronto, Canada). All other AR ligandswere
synthesized at GlaxoSmithKline. 5xGal4Luc3, MMTV-Luc, pcDNA-AR1-660,
and VP16-AR507-919 were described previously (Chang et al., 2005; Chang
and McDonnell, 2002). For AR mammalian two-hybrid assays, all insert
sequences corresponding to AR-interacting clones were subcloned into the
Gateway entry vector pENTR2B (Invitrogen, Carlsbad, CA) followed by recom-
bination into the pM mammalian two-hybrid vector (Clontech, Mountain View,
CA) that was Gateway enabled (pM-GB). pSG5-AR was a gift from T. Willson
(GlaxoSmithKline, Durham, NC). pCMX-Gal4-C’SMRT was a gift from J.D.
Chen (University of Medicine and Dentistry of New Jersey, Newark, NJ).
pM-ARA54 was generated by polymerase chain reaction (PCR) amplification
of ARA54 cDNA (corresponding to aa 361–474), followed by subcloning
into the pM vector. phRL-CMV (Renilla-Luc) was purchased from Promega
(Madison, WI).
T7 Phage Display
Full-length baculovirus purified AR was used as bait to screen for T7 phage
expressing AR-interacting proteins. Additional details can be found in Supple-
mental Experimental Procedures.
Transfection Assays
HepG2 cells weremaintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS, Invitrogen). For transfection,
cells were seeded into either 24 or 96 well cell culture plates in DMEM supple-
mented with charcoal stripped serum (Hyclone, Logan, UT) and were trans-
fected with Lipofectin (Invitrogen) according to the manufacturer’s instruc-
tions. For AR mammalian two-hybrid assays, the DNA mixture transfected
into the cells consisted of VP16-AR, 5XGalLuc3, pM-T7 clone, and pCMV-
bGal. For AR N- and C-terminal interaction assays, the DNAmixture consisted
of pcDNA-AR1-660, VP16-AR507-919, MMTV-luciferase and pCMV-bGal. For
AR transcriptional assays, the DNA mixture consisted of pSG5-AR, MMTV-
luciferase, and pCMV-bGal. For AR cofactor profiling assays, the DNAmixture
consisted of VP16-AR, 5XGalLuc3, pM-T7 clone, and phRL-CMV. Immedi-
ately following transfection, cells were induced with hormone for 48 hr. CellsLtd All rights reserved
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Protein Interaction Profiles Define AR Pharmacologywere then lysed and firefly luciferase (reporter) and b-galactosidase (transfec-
tion normalization) assays were performed. For AR-cofactor profiling assays,
Renilla luciferase assay was used as control for transfection efficiency.
Proliferation Assay
LaPC4 cells were maintained in Iscove’s DMEM supplemented with 15% FCS
plus R1881 (0.1 nM). For proliferation assays, cells were plated in 96well plates
in Iscove’s DMEM supplemented with charcoal stripped FCS (15%) at 10,000
cells/well. Following 72 hr incubation, cells were induced with ligand or vehicle
treatment. Cells were inducedwith ligand an additional two times at 72 hr inter-
vals. Twenty-four hours after the final hormone treatment, cells were assayed
for DNA content using Hoechst dye (excitation 346 nm, emission 460 nm).
RNA Isolation and Real-Time PCR
LaPC4 cells were treated for 24 hr with ligand and RNA was isolated using the
Aurum total RNA isolation kit (Bio-Rad, Hercules, CA). RNA (1 mg) was
reverse transcribed using the Bio-Rad iScript cDNA synthesis kit. Real-time
PCR was performed using the Applied Biosystems (Foster City, CA) 7300
instrument and iQ SYBR Green supermix (Bio-Rad). GAPDH expression was
used to normalize all real-time data. Sequences for gene-specific primers
can be found in Table S3.
Statistics
For gene ontology analysis, the relative overrepresentation of GO protein
modules was established using ONTO-Express (Draghici et al., 2003) and
Source (http://source.stanford.edu/cgi-bin/source/sourceSearch). Additional
details can be found in Supplemental Experimental Procedures.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
figures, and three tables and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00044-1.
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